Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment

Biogen Inc. (NASDAQ:BIIB) on Thursday agreed to acquire Massachusetts-based Alcyone Therapeutics for $85 million.

Alcyone will also receive certain milestones payable related to the development and regulatory approval of ThecaFlex DRx with nusinersen and additional pipeline products, securing all rights to ThecaFlex DRx.

As part of an existing partnership with Alcyone Therapeutics, the companies are advancing ThecaFlex DRx, an implantable subcutaneous port and catheter device being investigated for the intrathecal delivery of antisense oligonucleotides (ASOs).

Also Read: FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer’s Therapy

ThecaFlex DRx is designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and accessibility for a broader population with neurologic disorders.

Upon closing, Alcyone employees who will join Biogen will be integrated into the company’s product delivery solutions team, building upon the existing portfolio and expertise in drug-device combination products.

The ThecaFlex DRx System is initially being evaluated with Spinraza (nusinersen) in patients with spinal muscular atrophy, which will inform pathways for Biogen’s broader portfolio of investigational therapies.

Biogen and Alcyone Therapeutics have collaborated since 2023 on the development of ThecaFlex DRx, with the PIERRE and PIERRE-PK clinical studies for nusinersen currently underway.

Nusinersen is currently marketed under the brand name Spinraza and is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Biogen plans to introduce the new drug delivery system for Spinraza in early 2028, contingent upon the successful completion of clinical trials and regulatory approval.

With the acquisition, Biogen expects to oversee the end-to-end development, manufacturing, and commercialization of ThecaFlex DRx, while Alcyone’s remaining therapeutic assets, along with its Falcon precision intra-cerebrospinal fluid (CSF) drug transport modeling and intraparenchymal delivery, will be divested into a new independent company, Neela Therapeutics, Inc.

The transaction will include a convertible debt financing in Neela Therapeutics, Inc. from existing investors, including Biogen.

BIIB Price Action: Biogen shares were down 0.53% at $144.10 at the time of publication on Thursday. The stock is trading within its 52-week range of $110.03 to $204.18, according to Benzinga Pro data.

Read Next:

• Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Photo: jittawit21/Shutterstock